B. Riley Has Bearish Forecast for InfuSystem FY2025 Earnings

InfuSystem Holdings, Inc. (NYSE:INFU) – Research analysts at B. Riley dropped their FY2025 earnings estimates for shares of InfuSystem in a report issued on Tuesday, November 4th. B. Riley analyst A. Schock now anticipates that the company will post earnings per share of $0.29 for the year, down from their prior forecast of $0.30. The consensus estimate for InfuSystem’s current full-year earnings is $0.15 per share. B. Riley also issued estimates for InfuSystem’s Q4 2025 earnings at $0.07 EPS.

Other equities analysts have also recently issued reports about the company. Zacks Research cut InfuSystem from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Lake Street Capital initiated coverage on shares of InfuSystem in a research report on Monday, September 22nd. They set a “buy” rating and a $15.00 price target for the company. Finally, Roth Capital reissued a “buy” rating and issued a $14.00 price target (up from $13.00) on shares of InfuSystem in a research note on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $14.50.

InfuSystem Trading Up 2.9%

Shares of InfuSystem stock opened at $10.29 on Friday. The stock has a 50 day moving average of $10.07 and a 200 day moving average of $7.67. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98. The firm has a market capitalization of $210.18 million, a price-to-earnings ratio of 171.53 and a beta of 1.80. InfuSystem has a fifty-two week low of $4.61 and a fifty-two week high of $11.04.

Institutional Investors Weigh In On InfuSystem

Several institutional investors have recently modified their holdings of the company. CWM LLC increased its holdings in InfuSystem by 1,160.1% in the second quarter. CWM LLC now owns 4,826 shares of the company’s stock valued at $30,000 after buying an additional 4,443 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of InfuSystem during the 2nd quarter worth about $33,000. Jump Financial LLC purchased a new position in shares of InfuSystem in the 1st quarter valued at about $58,000. Williams & Novak LLC acquired a new stake in shares of InfuSystem during the 2nd quarter worth about $77,000. Finally, Virtu Financial LLC purchased a new stake in InfuSystem during the first quarter worth approximately $86,000. 71.13% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Scott Shuda sold 5,752 shares of the business’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $9.67, for a total transaction of $55,621.84. Following the completion of the transaction, the director directly owned 94,000 shares of the company’s stock, valued at approximately $908,980. The trade was a 5.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 11.40% of the company’s stock.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.